FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

Followed categories will be added to My News. The study, the biggest of its kind, discovered the effects of prematurity ...

While babies born at full term after a gestation period of nine months weigh around 2.5 to 4 kg, this one was weak with ...

"Oak Hill Bio and Chiesi’s BPD prevention trial enrols first European subject" was originally created and published by ...

This letter was submitted in response to the column "In Corruption Case Against Eric Adams, Prosecutors Are Attempting to ...

Metabolic dysfunction-associated steatohepatitis, or MASH, is a kind of chronic liver inflammation and scarring caused by ...

Helping Premature and Medically Fragile Infants Thrive Through the Gift of Donor Breast Milk SAN JOSE, CA / ACCESSWIRE / ...

Oxygen has been identified as a key element in the delay in retinal maturation and in the development of ROP. Vascular endothelial growth factor (VEGF) is an oxygen-mediated factor that is ...

A woman who started a prematurity awareness day after her twin grandchildren were born 15 weeks early is set to host the event for the fifth time ...

FELIQS®, a clinical stage multinational biopharmaceutical company focused on the development of first-in-class small molecules targeting lipid oxidation, announced today that the U.S. Food and Drug ...

Janney Montgomery Scott LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.4% ...

The FDA also granted orphan drug designation to FLQ-101 earlier in 2024. FELIQS is preparing to submit an investigational new ...